Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7508 and REGN9933 vs Apixaban in Atrial Fibrillation
NCT07175428Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Feb 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of cenvacibart, amrecibart in Atrial fibrillation (AFib), sponsored by Regeneron Pharmaceuticals. Started Oct 2025; status: recruiting.
02
Drugs
cenvacibartamrecibart
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07175428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175428.